Precision immunotherapies

Avidea is leveraging innovations in polymer-drug conjugate (PDC) technologies to develop safer and more effective immunotherapies for treating cancer, autoimmunity and infectious diseases.

View pipeline

Our technology

Avidea’s polymer-drug conjugate (PDC) platforms overcome key hurdles for enabling successful immunotherapies. Learn more

SNAPvax™

  • Modular vaccine capable of co-delivering any antigen(s) and immunomodulator(s) in self-assembling nanoparticles with precise size and composition
  • Most efficient T cell priming platform reported to-date
  • Applications: cancer, autoimmunity and infectious diseases

Syntholytic™

  • Synthetic, virus-sized star polymer combines direct tumor killing with immune stimulation, akin to oncolytic viruses, without the drawbacks
  • Dual responsive properties for targeted accumulation and selective drug release in tumor
  • Applications: metastatic tumor targeting

TRAPD™

  • Nanoparticle formation occurs after injection thereby trapping drug in tissues where it is needed
  • Reduces dosing frequency in volume restricted tissue
  • Applications: retains drugs in the eye, CNS and joints

Our team

Our team is building on more than two decades of pioneering work by our world-class scientific founders and advisors who are experts in immunology, oncology, vaccines and biomaterials.

About us

Careers

Avidea is looking for highly motivated and talented individuals to join our team. Check out our careers page to learn about opportunities to join our growing team.

Join us

Avidea's products are built on strong scientific principles

Scientific principles underlying technology platforms

In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.

Read more

Description of SNAPvax as a platform for promoting T cell immunity

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Read more

Immunological mechanisms for enhanced efficacy by intravenous vaccination

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.

Read more

Avidea in the news

May 17, 2021

Avidea Technologies and University of Maryland Awarded Grant to Evaluate Avidea’s SNAPvaxTM Tolerance Vaccine (TV) for Treating Autoimmune Diseases

More...

March 25, 2021

Avidea to present at World Immunotherapy Congress on March 29th and NeoAg Summit on April 21st.

November 2, 2020

Avidea Technologies and Collaborators Publish Results in Nature Immunology Showing SNAPvaxTM Cancer Vaccine Administered IV Generates Stem-Like (TCF1+) Neoantigen-Sepcific CD8+ T cells Resulting in Improved Efficacy

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

More...

March 9, 2020

Nature Biotechnology features Avidea’s self-assembling nanoparticle technology, SNAPvax (SNP-7/8a) on the Cover of its March 2020 issue

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens